Analysis of PI3K/mTOR Pathway Biomarkers and Their Prognostic Value in Women with Hormone Receptor–Positive, HER2-Negative Early Breast Cancer Hamdy.

Slides:

Advertisements

Similar presentations

Shaping Genetic Alterations in Human Cancer: The p53 Mutation Paradigm Thierry Soussi, Klas G. Wiman Cancer Cell Volume 12, Issue 4, Pages (October.

Advertisements

Combined PTEN Mutation and Protein Expression Associate with Overall and Disease- Free Survival of Glioblastoma Patients Jie Xu, Zhaoli Li, Jilin Wang,

CYFRA 21-1 as a Prognostic and Predictive Marker in Advanced Non–Small-Cell Lung Cancer in a Prospective Trial: CALGB Martin J. Edelman, MD, Lydia.

Pathologic response after neoadjuvant chemotherapy predicts locoregional control in patients with triple negative breast cancer Victor E. Chen, BS, Erin.

Frances A Shepherd, MD, Rafael Rosell, MD Journal of Thoracic Oncology

Expression Levels of KMT2C and SLC20A1 Identified by Information-theoretical Analysis Are Powerful Prognostic Biomarkers in Estrogen Receptor-positive.

miR p Is a Novel Prognostic Biomarker of Prostate Cancer

Angiogenesis and Antiangiogenesis in Triple-Negative Breast cancer

Primary Signet-Ring Carcinoma (SRC) of the Lung: A Population-Based Epidemiologic Study of 262 Cases with Comparison to Adenocarcinoma of the Lung Sai-Hong.

Clinical and the Prognostic Characteristics of Lung Adenocarcinoma Patients with ROS1 Fusion in Comparison with Other Driver Mutations in East Asian Populations

Laparoscopic Versus Open Radical Nephrectomy for Renal Cell Carcinoma: a Systematic Review and Meta-Analysis Gang Liu, Yulei Ma, Shouhua Wang, Xiancheng.

Distinct Patterns of Stromal and Tumor Expression of ROR1 and ROR2 in Histological Subtypes of Epithelial Ovarian Cancer C.E. Henry, C. Emmanuel, N.

Cancer: Inappropriate Expression of Stem Cell Programs?

Matteo Centonze, Concetta Saponaro, Anita Mangia

The Chemokine Receptor CXCR4 and c-MET Cooperatively Promote Epithelial- Mesenchymal Transition in Gastric Cancer Cells Yu Cheng, Yongxi Song, Jinglei.

A Pro-metastatic tRNA Pathway

Can Imaging Parameters Provide Information Regarding Histopathology in Head and Neck Squamous Cell Carcinoma? A Meta-Analysis Alexey Surov, Hans Jonas.

High Expression of PHGDH Predicts Poor Prognosis in Non–Small Cell Lung Cancer Jinhong Zhu, Jianqun Ma, Xudong Wang, Tianjiao Ma, Shu Zhang, Wei Wang,

A Comparative Performance Analysis of Multispectral and RGB Imaging on HER2 Status Evaluation for the Prediction of Breast Cancer Prognosis Wenlou Liu,

IRS-1: Auditing the effectiveness of mTOR inhibitors

The Path(way) Less Traveled: A Pathway-Oriented Approach to Providing Information about Precision Cancer Medicine on My Cancer Genome Alexandria D. Taylor,

Characterization of Aurora A and Its Impact on the Effect of Cisplatin-Based Chemotherapy in Patients with Non–Small Cell Lung Cancer Peng Kuang, Zuhua.

A Mitochondrial Power Play in Lymphoma

The Birds, the Bees, and Innate Immunity

Increased MAPK1/3 Phosphorylation in Luminal Breast Cancer Related with PIK3CA Hotspot Mutations and Prognosis Diana Ramirez-Ardila, A. Mieke Timmermans,

Negative Thyroid Transcription Factor 1 Expression Defines an Unfavorable Subgroup of Lung Adenocarcinomas Yiliang Zhang, MD, Rui Wang, MD, PhD, Yuan.

Prognostic Significance of TAZ Expression in Resected Non-Small Cell Lung Cancer Mian Xie, MD, PhD, Li Zhang, MD, Chao-Sheng He, MD, Jin-Hui Hou, MD,

Prognostic Significance of C-Reactive Protein and Smoking in Patients with Advanced Non-small Cell Lung Cancer Treated with First-Line Palliative Chemotherapy

Uncovering a Tumor Suppressor for Triple-Negative Breast Cancers

PTEN Enters the Nuclear Age

The p27Kip1 tumor suppressor gene: Still a suspect or proven guilty?

Volume 22, Issue 6, Pages (December 2012)

Frank Detterbeck, MD Journal of Thoracic Oncology

Combined Analysis of Molecular and Clinical Predictors of Gefitinib Activity in Advanced Non–Small Cell Lung Cancer: Epidermal Growth Factor Receptor.

Volume 3, Issue 4, Pages (April 2003)

Aberrant Wnt1/β-Catenin Expression is an Independent Poor Prognostic Marker of Non- small Cell Lung Cancer After Surgery Xianhua Xu, MD, Ping-Li Sun,

Characterizing the Killer Colorectal Carcinomas

IRS-1: Auditing the effectiveness of mTOR inhibitors

LKB1 Regulated Pathways in Lung Cancer Invasion and Metastasis

Interstitial tumor-associated macrophages combined with tumor-derived colony- stimulating factor-1 and interleukin-6, a novel prognostic biomarker in non–small.

Impact of Positive Nodal Metastases in Patients with Thymic Carcinoma and Thymic Neuroendocrine Tumors Benny Weksler, MD, Anthony Holden, MD, Jennifer.

Translational Control by the Eukaryotic Ribosome

Erik Jakobsen, Maria Iachina, Karen Ege Olsen, Anders Green

The Ribosome Emerges from a Black Box

Tumor-Infiltrating Foxp3+ Regulatory T Cells are Correlated with Cyclooxygenase-2 Expression and are Associated with Recurrence in Resected Non-small.

Extratumoral Vascular Invasion Is a Significant Prognostic Indicator and a Predicting Factor of Distant Metastasis in Non-small Cell Lung Cancer Yoshihisa.

LKB1 and Src: Antagonistic Regulators of Tumor Growth and Metastasis

Phase II Study of the Histone Deacetylase Inhibitor Romidepsin in Relapsed Small Cell Lung Cancer (Cancer and Leukemia Group B 30304) Gregory A. Otterson,

Specificities of Lung Adenocarcinoma in Women Who Have Never Smoked

A Translational View of the Molecular Pathogenesis of Lung Cancer

Clinical and the Prognostic Characteristics of Lung Adenocarcinoma Patients with ROS1 Fusion in Comparison with Other Driver Mutations in East Asian Populations

Forced Expiratory Volume in One Second as a Prognostic Factor in Advanced Non- small Cell Lung Cancer Jin Hwa Lee, MD, PhD, Eun Mi Song, MD, Yun Su Sim,

Clinical Relevance of Our Multimodality Prognostic Score

Genome-Wide SNP Analysis in Cancer: Leukemia Shows the Way

Volume 8, Issue 1, Pages (July 2014)

A Phase II Study of Carboplatin, Etoposide, and Exisulind in Patients with Extensive Small Cell Lung Cancer: CALGB 30104 Ramaswamy Govindan, MD, Xiaofei.

A common pathway for genetic events leading to pheochromocytoma

Tailor Made Protein Synthesis for HSCs

Padmanee Sharma, James P. Allison Cell

All Roads Lead to the Ribosome

Surveillance Epidemiology and End Results Evaluation of the Role of Surgery for Stage I Small Cell Lung Cancer James B. Yu, MD, Roy H. Decker, MD, PhD,

Volume 17, Issue 2, Pages (February 2010)

Kaplan–Meier curves for RFS and OS by various marker groups.

Quantitative PTEN protein expression is associated with pertuzumab sensitivity in vitro and trastuzumab resistance in vivo. Quantitative PTEN protein expression.

Volume 12, Issue 6, Pages (December 2007)

Anthony N. Imbalzano, Stephen N. Jones Cancer Cell

In This Issue Cell Volume 145, Issue 3, (April 2011)

Turning Reciprocal Feedback Regulation into Combination Therapy

Skp2, the FoxO1 hunter Cancer Cell

Volume 3, Issue 4, Pages (April 2003)

Presentation transcript:

Analysis of PI3K/mTOR Pathway Biomarkers and Their Prognostic Value in Women with Hormone Receptor–Positive, HER2-Negative Early Breast Cancer Hamdy A. Azim, Loay Kassem, Isabelle Treilleux, Qing Wang, Mona Abu El Enein, Shady E. Anis, Thomas Bachelot Translational Oncology Volume 9, Issue 2, Pages 114-123 (April 2016) DOI: 10.1016/j.tranon.2016.01.001 Copyright © 2016 Pfizer Inc. Terms and Conditions

Figure 1 Different molecules involved in the mTOR activation cascade. Studied molecules (marked with green rectangles) are PI3K mutations, pAKT, LKB1, pS6 ribosomal protein, and p4E-BP. Adapted with modifications from Azim et al [3]. Translational Oncology 2016 9, 114-123DOI: (10.1016/j.tranon.2016.01.001) Copyright © 2016 Pfizer Inc. Terms and Conditions

Figure 2 A flowchart of the whole population and subsets tested for different biomarkers. Translational Oncology 2016 9, 114-123DOI: (10.1016/j.tranon.2016.01.001) Copyright © 2016 Pfizer Inc. Terms and Conditions

Figure 3 Representative images of microscopic pictures showing tumor cells with high expression of nuclear LKB1 (A), cytoplasmic LKB1 (B) and low expression of LKB1 (C). Tumor cells with high expression of nuclear pAKT (D), cytoplasmic pAKT (E), and low expression of pAKT (F). Tumor cells with high (G) and low (H) expression of p4E-BP1, and tumor cells with high (I) and low (J) expression of pS6RP. Translational Oncology 2016 9, 114-123DOI: (10.1016/j.tranon.2016.01.001) Copyright © 2016 Pfizer Inc. Terms and Conditions

Figure 4 Kaplan-Meier curves of RFS (months) across different levels of biomarker expression: high (green) versus low (dotted blue) expression of nuclear and cytoplasmic LKB1, nuclear and cytoplasmic pAKT, p-4E-BP1, and p-S6RP. Translational Oncology 2016 9, 114-123DOI: (10.1016/j.tranon.2016.01.001) Copyright © 2016 Pfizer Inc. Terms and Conditions